Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.

Sievers C, Meira M, Hoffmann F, Fontoura P, Kappos L, Lindberg RL.

Clin Immunol. 2012 Jul;144(1):70-9. doi: 10.1016/j.clim.2012.04.002. Epub 2012 May 2.

PMID:
22659298
2.

Altered expression of miR-17-5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients.

Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L.

Eur J Immunol. 2010 Mar;40(3):888-98. doi: 10.1002/eji.200940032.

3.

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

J Immunol Res. 2014;2014:897249. doi: 10.1155/2014/897249. Epub 2014 May 12.

4.

MiR-126: a novel route for natalizumab action?

Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RL.

Mult Scler. 2014 Sep;20(10):1363-70. doi: 10.1177/1352458514524998. Epub 2014 Mar 5.

PMID:
24598267
5.

Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls.

Keller A, Leidinger P, Lange J, Borries A, Schroers H, Scheffler M, Lenhof HP, Ruprecht K, Meese E.

PLoS One. 2009 Oct 13;4(10):e7440. doi: 10.1371/journal.pone.0007440.

6.

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.

Waschbisch A, Atiya M, Linker RA, Potapov S, Schwab S, Derfuss T.

PLoS One. 2011;6(9):e24604. doi: 10.1371/journal.pone.0024604. Epub 2011 Sep 16.

7.

Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis.

Fenoglio C, Cantoni C, De Riz M, Ridolfi E, Cortini F, Serpente M, Villa C, Comi C, Monaco F, Mellesi L, Valzelli S, Bresolin N, Galimberti D, Scarpini E.

Neurosci Lett. 2011 Oct 17;504(1):9-12. doi: 10.1016/j.neulet.2011.08.021. Epub 2011 Aug 19.

PMID:
21875645
8.

miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M.

Gene. 2014 Jul 10;544(2):128-33. doi: 10.1016/j.gene.2014.04.069. Epub 2014 Apr 30.

PMID:
24792898
9.

Differential microRNA expression in blood in multiple sclerosis.

Søndergaard HB, Hesse D, Krakauer M, Sørensen PS, Sellebjerg F.

Mult Scler. 2013 Dec;19(14):1849-57. doi: 10.1177/1352458513490542. Epub 2013 Jun 17.

PMID:
23773985
11.

Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients.

von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, Damasceno BP, Santos LM, Brandão CO.

Mult Scler. 2012 Jul;18(7):1038-41. doi: 10.1177/1352458511428465. Epub 2011 Oct 31.

PMID:
22041091
12.

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.

Harrer A, Pilz G, Einhaeupl M, Oppermann K, Hitzl W, Wipfler P, Sellner J, Golaszewski S, Afazel S, Haschke-Becher E, Trinka E, Kraus J.

PLoS One. 2012;7(2):e31784. doi: 10.1371/journal.pone.0031784. Epub 2012 Feb 20.

13.

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.

Krumbholz M, Meinl I, Kümpfel T, Hohlfeld R, Meinl E.

Neurology. 2008 Oct 21;71(17):1350-4. doi: 10.1212/01.wnl.0000327671.91357.96.

PMID:
18936427
14.

Natalizumab for relapsing-remitting multiple sclerosis.

Horga A, Tintoré M.

Neurologia. 2011 Jul-Aug;26(6):357-68. doi: 10.1016/j.nrl.2010.10.004. Epub 2010 Dec 28. Review. English, Spanish.

15.

Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study.

Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Décard BF, Thum T, Gold R.

Neurology. 2012 Nov 27;79(22):2166-70. doi: 10.1212/WNL.0b013e3182759621. Epub 2012 Oct 17.

PMID:
23077021
16.

miR-15a and 16-1 are downregulated in CD4+ T cells of multiple sclerosis relapsing patients.

Lorenzi JC, Brum DG, Zanette DL, de Paula Alves Souza A, Barbuzano FG, Dos Santos AC, Barreira AA, da Silva WA.

Int J Neurosci. 2012 Aug;122(8):466-71. doi: 10.3109/00207454.2012.678444. Epub 2012 May 1.

PMID:
22463747
17.

Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.

Sørensen PS, Jensen PE, Haghikia A, Lundkvist M, Vedeler C, Sellebjerg F, Koch-Henriksen N, Fogdell-Hahn A, Myhr KM, Hillert J, Gold R.

Mult Scler. 2011 Sep;17(9):1074-8. doi: 10.1177/1352458511404271. Epub 2011 Apr 20.

PMID:
21511692
18.

CD49d expression as a promising biomarker to monitor natalizumab efficacy.

Defer G, Mariotte D, Derache N, Toutirais O, Legros H, Cauquelin B, Le Mauff B.

J Neurol Sci. 2012 Mar 15;314(1-2):138-42. doi: 10.1016/j.jns.2011.10.005. Epub 2011 Nov 1.

PMID:
22050952
19.

Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism.

Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E.

J Clin Immunol. 2011 Aug;31(4):623-31. doi: 10.1007/s10875-011-9522-x. Epub 2011 Apr 14.

20.

[Natalizumab and reduction of carbonylated proteins in patients with multiple sclerosis].

Tasset I, Aguera E, Gascon F, Giraldo AI, Salcedo M, Cruz AH, Sanchez F, Tunez I.

Rev Neurol. 2012 Apr 16;54(8):449-52. Spanish.

Supplemental Content

Support Center